selectively inhibiting attachment of said cells to said vitronectin.

49. A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising providing to said cells *in vitro* a solution containing a peptide that encompasses the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting binding of said vitronectin receptor-containing cells to said substrate.

50. A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising providing to said cells *in vivo* a solution containing a peptide that encompasses the sequence Arg-Gly-Asp, said Arg-Gly-Asp sequence being conformationally restricted, thereby selectively inhibiting binding of said vitronectin receptor-containing cells to said substrate.

51. A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising the steps of:

a. providing to said cells *in vitro* a peptide containing the sequence Arg-Gly-Asp in solution, said Arg-Gly-Asp sequence being conformationally restricted; and

b. contacting said cells with said solution.

52. A method of selectively inhibiting binding of vitronectin receptor-containing cells to a substrate comprising the steps of:

a. providing to said cells *in vivo* a peptide containing the sequence Arg-Gly-Asp in solution, said Arg-Gly-Asp sequence being conformationally restricted; and

b. contacting said cells with said solution.

53. A method of selectively inhibiting binding of cells to a substrate comprising providing to said cells *in vitro* a solution of a peptide containing an Arg-Gly-Asp sequence chemically modified with an additional chemical structure, wherein said additional chemical structure conformationally restricts the stereochemical structure of said Arg-Gly-Asp sequence in such a way that the affinity of the Arg-Gly-Asp binding site sequence for a particular receptor is enhanced.

54. A method of selectively inhibiting binding of cells to a substrate comprising providing to said cells *in vivo* a solution of a peptide containing an Arg-Gly-Asp sequence chemically modified with an additional chemical structure, wherein said additional chemical structure conformationally restricts the stereochemical structure of said Arg-Gly-Asp sequence in such a way that the affinity of the Arg-Gly-Asp binding site sequence for a particular receptor is enhanced.

REMARKS

Claims 45 through 54 are presently pending and under examination. Claims 47 through 54 have been amended herein.